| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 68001-0629-36 | 68001-0629 | DOXORUBICIN HYDROCHLORIDE | DOXORUBICIN HYDROCHLORIDE | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Jan 7, 2025 | In Use | |
| 68382-0074-06 | 68382-0074 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Dec 5, 2017 | In Use | |
| 50242-0070-86 | 50242-0070 | Obinutuzumab | Gazyva | 1000.0 mg/40mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Nov 4, 2013 | In Use | |
| 60505-6271-01 | 60505-6271 | Azacitidine | Azacitidine | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Jan 23, 2024 | In Use | |
| 51655-0809-04 | 51655-0809 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov 7, 2022 | In Use | |
| 68382-0245-05 | 68382-0245 | Imatinib mesylate | Imatinib mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jan 21, 2021 | In Use | |
| 80425-0469-01 | 80425-0469 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec 29, 2024 | In Use | |
| 00591-2435-15 | 00591-2435 | Isotretinoin | Isotretinoin | 30.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Apr 29, 2021 | In Use | |
| 47335-0890-75 | 47335-0890 | Temozolomide | Temozolomide | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb 13, 2014 | In Use | |
| 25000-0011-27 | 25000-0011 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Apr 27, 2017 | In Use | |
| 50742-0481-20 | 50742-0481 | FLUOROURACIL | FLUOROURACIL | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Dec 21, 2019 | In Use | |
| 50090-0100-07 | 50090-0100 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov 28, 2014 | Apr 30, 2018 | In Use |
| 53808-0411-01 | 53808-0411 | Capecitabine | Xeloda | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Jul 1, 2009 | In Use | |
| 54868-4287-04 | 54868-4287 | Tamoxifen Citrate | Tamoxifen Citrate | 20.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Jan 17, 2005 | In Use | ||
| 33261-0417-09 | 33261-0417 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 31, 2007 | In Use | |
| 70518-1105-01 | 70518-1105 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Apr 10, 2018 | In Use | |
| 70518-2172-00 | 70518-2172 | Prednisone | Prednisone | 1.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jun 28, 2019 | In Use | |
| 54569-0327-00 | 54569-0327 | Methylprednisolone | Medrol | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Oct 24, 1957 | In Use | |
| 55150-0262-03 | 55150-0262 | Methylprednisolone Sodium Succinate | Methylprednisolone Sodium Succinate | 40.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intramuscular, Intravenous | Dec 15, 2015 | In Use | |
| 46708-0678-02 | 46708-0678 | Docetaxel | Docetaxel | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Feb 28, 2023 | In Use | |
| 63323-0735-10 | 63323-0735 | Pamidronate Disodium | Pamidronate Disodium | 9.0 mg/mL | Ancillary Therapy | Bisphosphonate | Intravenous | May 19, 2002 | Aug 27, 2015 | In Use | |
| 70860-0201-10 | 70860-0201 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Mar 15, 2017 | In Use | |
| 54868-5759-00 | 54868-5759 | Dasatinib | Sprycel | 70.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Feb 12, 2007 | In Use | |
| 43598-0512-63 | 43598-0512 | Lenalidomide | Lenalidomide | 10.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 6, 2022 | In Use | |
| 50742-0494-17 | 50742-0494 | Levoleucovorin | LEVOLEUCOVORIN | 10.0 mg/mL | Ancillary Therapy | Chemoprotective | Antidote | Intravenous | May 8, 2018 | Jul 31, 2021 | In Use |
Found 12611 results — Export these results
Home